A Study of LY3502970 in Japanese Participants With Type 2 Diabetes Mellitus
| 대상 질환 | Diabetes Mellitus, Type 2 |
|---|---|
| 임상 단계 | 1상 |
| 스폰서 | Eli Lilly and Company |
| 상태 | 완료 |
| 참여자 수 | 62 명 |
| 중재(약물) | LY3502970 |
| 시작일 | 2021년 11월 12일 |
| 완료일 | 2022년 9월 5일 |
| 결과 공개일 | 2026년 7월 16일 |
요약
The main purpose of this study is to learn about the side effects of LY3502970 when given to Japanese participants with type 2 diabetes mellitus (T2DM). Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. For each participant, the study will last up to 24 weeks, inclusive of screening and will include 10 visits to the study center.
Number of Participants With One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
| Placebo - Part A | 2 Participants |
|---|---|
| 2 mg LY3502970 - Part A | 5 Participants |
| 3 mg LY3502970 - Part A | 5 Participants |
| Placebo QD - Part B | 4 Participants |
| 2(or 3)/3/6/12 mg LY3502970 QD - Part B | 11 Participants |
| 2/3/6/8/12/24 mg LY3502970 QD - Part B | 12 Participants |
BENITIONS에서 보기 ClinicalTrials.gov 원문 보기
같은 질환의 다른 임상
- Cardiovascular Outcomes in Bariatric Surgery Patients With Type 2 Diabetes — The Cleveland Clinic
- Diabetes Prevention Program Outcomes Study — National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Uric Acid Lowering Trial in Youth Onset T2D — University of Colorado, Denver
- Financial Incentives And Nurse Coaching to Enhance Diabetes Outcomes (FINANCE-DM)-1 — State University of New York at Buffalo
- Continuous Glucose Monitoring Following Hospital Discharge — Kathleen Dungan
- Skeletal Muscle Diacylglycerol and Sphingolipids - Impact of Localization and Species on I — University of Colorado, Denver